Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Collegium Pharmaceutical
COLL
5
Enerpac Tool
EPAC
(Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 25.02%690.17M | 21.09%2.52B | 24.52%663.53M | 20.47%604.69M | 18.85%695.44M | 20.64%552.05M | 20.42%2.08B | 22.49%532.86M | 21.83%501.94M | 19.10%585.15M |
Net investment income | -0.85%14.04M | 17.83%60.04M | -0.16%14.12M | 13.51%16.57M | 25.26%15.19M | 40.38%14.16M | 282.19%50.95M | 85.80%14.15M | 228.30%14.59M | 1,038.87%12.13M |
Fee revenue and other income | 25.70%676.13M | 21.17%2.46B | 25.19%649.41M | 20.68%588.13M | 18.71%680.25M | 20.19%537.89M | 18.39%2.03B | 21.37%518.72M | 19.58%487.35M | 16.89%573.02M |
-Fees and commissions | 25.70%676.13M | 21.17%2.46B | 25.19%649.41M | 20.68%588.13M | 18.71%680.25M | 20.19%537.89M | 18.39%2.03B | 21.37%518.72M | 19.58%487.35M | 16.89%573.02M |
Total expenses | 26.57%639.13M | 21.94%2.24B | 25.50%594.49M | 26.79%585.01M | 14.10%558.71M | 21.72%504.94M | 18.99%1.84B | 23.56%473.69M | 21.65%461.41M | 19.43%489.68M |
Selling general and administration | 19.35%536.35M | 21.66%1.94B | 27.01%514.78M | 20.94%481.93M | 14.53%497.02M | 25.03%449.39M | 20.46%1.6B | 23.70%405.32M | 23.34%398.5M | 21.03%433.97M |
-General and administrative expense | 19.35%536.35M | 21.66%1.94B | 27.01%514.78M | 20.94%481.93M | 14.53%497.02M | 25.03%449.39M | 20.46%1.6B | 23.70%405.32M | 23.34%398.5M | 21.03%433.97M |
Depreciation and amortization | 124.90%67.62M | 44.71%167.63M | 109.34%63.1M | 31.08%41.65M | 23.62%32.81M | 9.83%30.07M | 5.99%115.84M | 12.37%30.14M | 17.11%31.77M | -3.34%26.55M |
-Depreciation | 26.88%2.64M | 8.27%9.79M | 20.14%2.97M | 12.09%2.47M | 4.41%2.27M | -5.11%2.08M | 58.84%9.04M | 38.11%2.47M | 50.44%2.2M | 77.14%2.18M |
-Amortization | 132.19%64.99M | 47.80%157.85M | 117.29%60.13M | 32.50%39.18M | 25.33%30.54M | 11.13%27.99M | 3.09%106.8M | 10.53%27.67M | 15.21%29.57M | -7.11%24.37M |
Non-operating net interest income (expenses) | -85.40%-54.51M | -32.58%-158.45M | -63.59%-48.53M | -56.83%-49.39M | -7.78%-31.13M | 0.23%-29.4M | -14.00%-119.51M | -1.02%-29.67M | -9.10%-31.49M | -16.24%-28.88M |
-Interest expense-non operating | 85.40%54.51M | 32.58%158.45M | 63.59%48.53M | 56.83%49.39M | 7.78%31.13M | -0.23%29.4M | 14.00%119.51M | 1.02%29.67M | 9.10%31.49M | 16.24%28.88M |
Income from associates and other participating interests | -11.93%4.94M | 108.81%18.23M | 65.71%4.72M | 84.15%4.18M | 130.32%3.72M | 181.00%5.61M | 2,208.94%8.73M | --2.85M | 1,477.08%2.27M | 10,200.00%1.62M |
Special income (charges) | 21,503.08%14.04M | 521.67%22.86M | 2,326.90%23.67M | 119.75%365K | 30.79%-1.24M | 109.10%65K | -1,126.47%-5.42M | 16.89%-1.06M | -336.88%-1.85M | -815.54%-1.8M |
-Less:Restructuring and mergern&acquisition | -21,503.08%-14.04M | -521.67%-22.86M | -2,326.90%-23.67M | -119.75%-365K | -30.79%1.24M | -109.10%-65K | 1,126.47%5.42M | -16.89%1.06M | 336.88%1.85M | 815.54%1.8M |
Income before tax | 8.36%51.04M | 14.55%272.55M | 16.67%69.04M | -51.44%19.68M | 43.22%136.73M | 10.18%47.1M | 32.78%237.93M | 14.59%59.18M | 23.98%40.53M | 17.44%95.47M |
Income tax | 762.59%55.43M | -1.85%42.64M | 3,835.51%26.49M | -136.10%-8.96M | 60.44%18.69M | 2.08%6.43M | 172.64%43.45M | -88.51%673K | 627.85%24.83M | 4.32%11.65M |
Earnings from equity interest net of tax | ||||||||||
Net income | -110.79%-4.39M | 18.22%229.91M | -27.26%42.56M | 82.40%28.64M | 40.83%118.04M | 11.58%40.68M | 19.13%194.48M | 27.79%58.5M | -46.37%15.7M | 19.53%83.82M |
Net Income continuous operations | -110.79%-4.39M | 18.22%229.91M | -27.26%42.56M | 82.40%28.64M | 40.83%118.04M | 11.58%40.68M | 19.13%194.48M | 27.79%58.5M | -46.37%15.7M | 19.53%83.82M |
Minority interest income | -3.68%23.25M | 1.35%135.25M | -19.23%28.8M | -46.73%11.05M | 32.59%71.25M | 3.63%24.14M | 30.56%133.44M | 27.86%35.66M | 18.34%20.75M | 17.80%53.74M |
Net income attributable to the parent company | -267.17%-27.64M | 55.09%94.67M | -39.80%13.75M | 448.50%17.59M | 55.55%46.79M | 25.65%16.54M | -0.02%61.04M | 27.67%22.85M | -142.97%-5.05M | 22.76%30.08M |
Preferred stock dividends | ||||||||||
Other preferred stock dividend | -469.00%-369K | 483.25%1.56M | 344.44%550K | 101.24%10K | 431.90%697K | 160.61%100K | -4.91%-406K | |||
Net income attributable to common stockholders | -272.92%-27.64M | 55.12%94.67M | -31.86%15.09M | 448.90%17.96M | 48.38%45.23M | 19.42%15.99M | -1.34%61.03M | 22.34%22.15M | -143.22%-5.15M | 22.48%30.48M |
Basic earnings per share | -257.14%-0.22 | 47.17%0.78 | -42.11%0.11 | 475.00%0.15 | 40.74%0.38 | 16.67%0.14 | -7.02%0.53 | 18.75%0.19 | -136.36%-0.04 | 17.39%0.27 |
Diluted earnings per share | -269.23%-0.22 | 36.54%0.71 | -44.44%0.1 | 325.00%0.09 | 42.31%0.37 | 18.18%0.13 | 0.00%0.52 | 28.57%0.18 | -144.44%-0.04 | 18.18%0.26 |
Dividend per share | 9.09%0.12 | 0.44 | 0.11 | 0.11 | 0.11 | 0.11 | ||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |